- Home
- ERIC vs ONC Comparison
ERIC vs ONC Comparison
Compare ERIC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERIC
- ONC
- Stock Information
- Founded
- ERIC 1876
- ONC 2010
- Country
- ERIC Sweden
- ONC Cayman Islands
- Employees
- ERIC N/A
- ONC N/A
- Industry
- ERIC Radio And Television Broadcasting And Communications Equipment
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- ERIC Technology
- ONC Health Care
- Exchange
- ERIC Nasdaq
- ONC Nasdaq
- Market Cap
- ERIC 27.5B
- ONC 26.9B
- IPO Year
- ERIC N/A
- ONC N/A
- Fundamental
- Price
- ERIC $8.47
- ONC $228.38
- Analyst Decision
- ERIC Hold
- ONC Strong Buy
- Analyst Count
- ERIC 1
- ONC 7
- Target Price
- ERIC $9.80
- ONC $326.43
- AVG Volume (30 Days)
- ERIC 26.8M
- ONC 417.2K
- Earning Date
- ERIC 07-11-2025
- ONC 05-07-2025
- Dividend Yield
- ERIC 0.31%
- ONC N/A
- EPS Growth
- ERIC N/A
- ONC N/A
- EPS
- ERIC 0.05
- ONC N/A
- Revenue
- ERIC $24,863,989,204.00
- ONC $4,180,740,829.00
- Revenue This Year
- ERIC $1.11
- ONC $869.15
- Revenue Next Year
- ERIC $1.01
- ONC $19.07
- P/E Ratio
- ERIC $177.96
- ONC N/A
- Revenue Growth
- ERIC N/A
- ONC 51.16
- 52 Week Low
- ERIC $5.00
- ONC $141.31
- 52 Week High
- ERIC $8.90
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- ERIC 60.07
- ONC N/A
- Support Level
- ERIC $8.29
- ONC N/A
- Resistance Level
- ERIC $8.51
- ONC N/A
- Average True Range (ATR)
- ERIC 0.12
- ONC 0.00
- MACD
- ERIC 0.01
- ONC 0.00
- Stochastic Oscillator
- ERIC 89.47
- ONC 0.00
About ERIC Ericsson
Ericsson provides telecom equipment and services that are primarily used to build and facilitate mobile networks through operations in three segments: networks, cloud and software services, and enterprises. The firm's customers have historically been primarily wireless carriers, but the firm is making a push to cater more to other enterprises as well, both as they try to take advantage of 5G capabilities and on other "as-a-service" communications platforms. The company also licenses its patents to handset manufacturers so their devices are compatible with wireless networks.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.